Ion World 2017 was held last October 19 at CNIO, Centro Nacional de Investigaciones Oncológicas in Madrid, with the participation of Dr. Ana Patiño, from the Genomics Unit of CIMA LAB Diagnostics.

Dr. Patiño gave a session on the implementation, clinical utility and relevance of genetic results obtained through the analysis of gene panels based on NGS (Next Generation Sequencing) technology in adult cancer.

Thermo Fisher's essay Oncomine Focus is an NGS panel for the identification of clinically valid biomarkers in solid tumors. This test includes the identification of several genetic alterations (SNPs, indels, CNVs and rearrangements) related to the response to certain treatments in solid tumors: lung, breast, pancreatic, melanoma, colorectal cancer, as well as tumors of unknown origin. It is also a useful tool when establishing the identity between synchronous tumors or their relationship (primary tumor vs. metastasis).

This test is a sequencing test directed to 52 relevant actionable genes in solid tumors, for having predictive value of response to treatment or participation in clinical trials, through the use of massive sequencing, facilitating the diagnosis, prognosis and prediction of response to treatment in each individual patient.

Dr. Patiño commented on the experience of CIMA LAB Diagnostics in the use of this tool in patients of the Clínica Universidad de Navarra, both its accumulated experience in recent years, as well as relevant cases that would not have been adequately resolved with conventional technology.